Date of report 28 Jul 2020
Reported case interaction between
 Rilpivirine and CHLORPROMAZINE

FLS Science

Drugs suspected to be involved in the DDI

Rilpivirine
Daily Dose
25 (mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Jan. 23, 2018
End date
Ongoing
CHLORPROMAZINE
Daily Dose
150 (mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Jan. 1, 2017
End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment
Rilpivirine/Emtricitabine/Tenofovir-AF
Complete list of all comedications taken by the patient, included that involved in the DDI

Chlorpromazine 150 mg, Trazodone 225 mg, Bisoprolol 3.75 mg, Spironolocatone 100 mg, Pantoprazole 20 mg, Calcium carbonate 1000 mg, Furosemide 25 mg, Beclometasone/Formeterol, Atorvastatin 20 mg, Colecalciferol

Clinical case description

Gender
Male
Age
50
eGFR (mL/min)
>60
Liver function impairment
Yes
Child-Pugh
Child-Pugh A
Description

HIV/HBV/HCV coinfected patient on long-term HAART with good immunovirological status (CD4 562, HIV RNA not detectable, HBV DNA not detectable), and on SVR after treatment for HCV with DAAs. He is suffering from compensated liver cirrhosis (Child A), recurrent pancreatitis, hypertension, coronary artery disease (acute MI with coronary stent), asthma, and personality disorder/depression. Despite possible QT prolongation by chlorpromazine/trazodone and rilpivirine, cQT was <450 ms in the follow up. In addition, the patient showed sustained virological suppression despite continued use of pantoprazole/rilpivirine (RPV Ctrough 55 ng/mL; reference 67±30 ng/ml).

Clinical Outcome

No unwanted outcome

Editorial Comment

University of Liverpool Recommendation

Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
For more information click here